Agilent - UBS Life Science RS - library.corporate-ir.netlibrary.corporate-ir.net/library/10/103/103274/items/284497/Agilent... · Weakness seen Semiconductor markets. ... GSK, Novartis,

Page 1

Tuesday, March 11, 2008Santa Clara, CA

Agilent Technologies2008 UBS West Coast Life Sciences Bus Tour

Page 2


Nicolas (Nick) Roelofs, Ph.D.Vice President and General ManagerLife Sciences Solutions

Page 5

These presentations contain forward-looking statements (including, without limitation, statements regarding the enhancement of shareholder value, our ongoing share repurchase program, and information and future guidance on our goals, priorities, orders, revenues, demand, growth opportunities, customer service and innovation plans, new product introductions, financial condition, earnings, liquidity, capital structure, operating performance, cost structure, cyclicality, the continued strengths and expected growth of the markets we sell into, operations, operating earnings, balance sheet models and our ability to be free cash flow positive under any normal economic environment) that involve risks and uncertainties that could cause results of Agilent to differ materially from management’s current expectations.

In addition, other risks that the company faces in running its operations include the ability to execute successfully through business cycles while it continues to implement cost reductions; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross margin pressures; the risk that our cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties on our markets and our ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix, and other risks detailed in the company's filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the three month period ended January 31, 2008.

The company assumes no obligation to update the information in these presentations. These presentations and the Q&A that follows include non-GAAP numbers. A presentation of the most directly comparable GAAP numbers and the reconciliations between the non-GAAP and GAAP numbers can be found at http://www.investor.agilent.com under “GAAP Reconciliations” and accompany this slide set.

Safe Harbor Statement

Page 6

World’s Premier Measurement CompanyDelivers on Performance CommitmentsQ108 Financial Highlights

• Orders of $1.40 billion, up 12% from last year, revenues of $1.39 billion, up 9% from last year

• Q1 Operating EPS* of $0.42, up 8% year-over-year and came in at the high end of our guidance. Generated impressive ROIC of 23% despite increased, acquisition-related invested capital

• Strong working capital management - inventory days on hand improved by 3 days over last year, maintained peer-leading performance on days sales outstanding at 47 days

• Electronic Measurement revenue up 5% over last year reflecting balanced performance between General Purpose and Communications end markets. Aerospace & Defense, Wireless R&D and Wireless Manufacturing performed well. Weakness seen Semiconductor markets.

• Bio-Analytical revenue up 15% over last year (10% organic)—reflecting strength in our GC, GC/MS, LC and LC/MS product platforms across both Life Sciences and Chemical Analysis end markets. Food Safety up over 20% year-over-year

*presented on a non-GAAP basis

Page 7

FY06 Revenue$900 Million

FY06 Revenue$700 Million

FY06 Revenue$1.4 Billion

FY06 Revenue$2 Billion

Materials Sciences

$129M

Chemical Analysis

$1,041M

Life Sciences

$835M

Consumables, Service & Support

Wireless

$1,900M

ElectronicInstruments

$688M

Electronic Measurement2007 Revenue: $3.4 Billion

Expected 2008 Growth: 4-6%

Bio-Analytical Measurement2007 Revenue: $2.0 Billion

Expected 2008 Growth: 12-14%

Network andDigital

Solutions

$826M

Service & Support

Strategic Intent: Partner to every engineer, scientist and service provider in the $43B electronic and bio-analytical measurement markets

A Focused Measurement CompanySolutions that address critical customer challenges

Page 8

Market Opportunity and Agilent Revenue Distribution$43 billion market - $5.4 billion revenue (FY07)

GENERAL PURPOSE COMMUNICATIONS

LIFE SCIENCES CHEMICAL ANALYSISBio-Analytical Measurement

$6B$14B

$7.5B$13B

$40B Market

Revenue $1.4B (25% of Agilent)

Revenue $2.0B (38% of Agilent)

Revenue $1.2B (21% of Agilent)Revenue $0.8B (16% of Agilent)

Electronic Measurement

13% Pharma, Biotech

Academia and Gov’t 3%

Market % Agilent Market Growth

5-7%

% Agilent

FoodForensics

PetrochemicalEnvironmental

4% 2% 7% 6%

10% Aerospace/Defense

General Industry

Computers/Semi

20% 8%

% Agilent 8% Wireless Manufacturing

Wireless R&D

Wireless Monitoring

7%

2% Wireline 5%

Other Comms 3%

Market % Agilent

Materials Science 2%

Market Market Growth

7-9%

Market Growth

5-6%

Market

MarketGrowth

5-6%

$43B Market

$8B$17B

$9B $9B

Page 9

Life Sciences FY07 revenue $835 million, FY07 growth 24%

Academic and Government(Not-For-Profit)

FY07 Revenue = $151M18% of total LSSU Revenue

Pharma/Biotech(For Profit)

FY07 Revenue = $684M82% of total LSSU Revenue

Life Sciences Market: $17B-Market Growth: 7-9%

LSSU FY08 expected growth 16-18%

Market Growth Drivers• Life Science applications – “omics”• Growth in generics and CROs • Academic and government investment

Agilent Actions• Life Science workflow solutions

•Refreshed and expanded core platforms•Expanded portfolio of reagents,consumables & services

• Applications focus

Page 10

Chemical Analysis FY07 revenue $1 billion, FY07 growth 18% (excludes materials science)

Chemical Analysis Market: $8B-Market Growth: 5-7%

CASU FY08 expected growth 9-11%

Market Growth Drivers• Food and environmental testing• Secular growth in developing countries• Petrochemical demand

Agilent Actions•Refreshed and expanded core portfolio •Geographic Initiatives – Asia, Eastern

Europe and Latin America•Applications focus •Expanding measurement platforms (AFM, TILL, Particles)

Petrochemical& Chemical

Testing

$0.4 B34% of CASU

revenue

EnvironmentalTesting

$0.3 B34% of total revenue

Food Testing $0.2 B22% of CASU

revenue

ForensicsTesting

$0.1 B11% of CASU

revenue

$0.3 B33% of CASU

revenue

Page 11

Life Sciences Customers and Competitors

Pharma/Biotech

Largest competitors:

• Waters• Thermo• ABI• Affymetrix

High Growth Areas:• Biologic Therapeutics• Outsourcing of Discovery & Development• New Capacity in India, China

Key Customers:GSK, Novartis, Sanofi-Aventis, Pfizer, Merck, Amgen, Roche, Lilly, J & J

Academic/GovernmentLargest competitors:

• ABI• Thermo• Affymetrix• GE (Pharmcia)

High Growth Areas:

• Functional Proteomics

• Applied Genomics

• Stem Cell Research

Key Customers:NIH, NCI, Sanger Center (UK)Univ. of California, SingaporeGenomic Institute, EORTC(Europe), Stanford

Page 12

Secular Growth StrategyMarket 6% + share gains 2% + acquisitions 2% = 10% goal

Life Sciences

$435M

$700M in Phase II Acquisitionsby Market Segment

Chemical Analysis $125M*

Communications $60M

General Purpose

$80M

(graph represents market segment sizes)

•Invest in the Core

•Strategic Growth Initiatives•Life Science•Materials Science•Wireless R&D•Surveillance and Homeland Security•Low-Cost Instrumentation

•Targeted M&A •Life Sciences workflow solutions•A/D and surveillance•Materials Science

*Includes buyout of Yokogawa Analytical Instruments JV

Page 13

Key Growth Initiatives

Sustain a double-digit revenue growth portfolio

Genomics Large and Small Molecule Analysis

Extend market leadership with innovative products, services and informatics

• Integrate Bio-Reagents into Agilent workflow solutions

• Leverage portfolio breadth across u-Fluidics, Microarray and qPCR

• Expand portfolios—LC/MS, Chip-LC, Bio-MS

• Focus on workflow solution development

Page 14

Life Science BusinessStrategy

Leading workflow partner for life science solutions in the Pharmaceutical and Academic/Government

markets.

Key Strategies:• Move all Life Sciences businesses to Agilent operating model• Drive market share in technology-expanding platforms – LC, LC/MS, microfluidics,

microarray • Build on the scaffold of Stratagene and Velocity11 to create new application based

opportunities• Expand market share in the Academic / Government market segments• Capitalize on geographic opportunities – Asia Pacific, Eastern Europe

and Latin America• Leverage Diagnostic Capabilities

Page 15

DetectionSeparationSample IntroSample Prep

Sample collection DetectionSeparationSample

Labeling Conversion

Kalabie

Data to Report SamplePrep

Life Science Solutions UnitLeading workflow partner for life science solutions

India Applications Team

Page 16

New Member to the BAM Family:

BioCel 1200

Element

VWorks

Multi-BioCel Platform

Bravo

BenchCel

Workstations VPrep

PlateLoc

VSpin VCode

Consumables

BioCel 1600

Systems

Software

Instruments

Consumables Service

Page 17

•Business Model Goal•Deliver > industry growth and ROIC•Cash flow positive throughout anypart of cycle•Flexible cost structure

Deliverables•Revenues > 8-10%; GM > 55%•Operating profit > 14% & ROIC of 21% over cycle•30-40% incremental operating profit (OP) on organic growth

Acquisitions•Deliver > 20% ROIC in 3-5 yrs•Technology purchases fit within existing cost structure

Variable Pay•ROIC and OP$ metrics align employees and shareholders•Provides automatic “flex” to cost structure through cycles

Agilent’s Business ModelDelivering above industry average EPS & ROIC

2001 2004 2007Gross Margin 46% 50% 56%Op Ex, % 43% 40% 40%Operating Margin 2% 10% 16%ROIC 3% 12% 27%

Inventory DOH 131 106 92Receivables DSO 57 54 46

FCF from Operations (73)$ 228$ 815$

Page 18

YoY Rev Growth 10% 10% 6% 15% 16% 11% 18%Inventory Days 73 112 57 101 71 83 80DSO 54 67 69 78 68 69 53ROIC 8% 17% 25% 41% 10% 23% 29%

59% 54%44% 43%

57%50% 46%

2% 7%

9% 5%

6%7% 8%

21% 27%29%

27%

24%26% 27%

17% 13% 18%25%18%13% 19%

0%

20%

40%

60%

80%

100%

ThermoFisher

Varian Applied Bio Waters Perkin Elmer Blend BAM

Op ProfitSG&AR&DCOGS

Bio-Analytical Competitive ComparisonsLast twelve months (as of January 31, 2008)*

*Agilent estimates of comparable proforma results

Page 19

Why Agilent Will Continue to Win ...

Leading positions in served available markets and growth geographies

Bio-Analytical Measurement

Customer Productivity

& Loyalty

Competitive Differentiation

&Drives

Operating Model drives profitable growth; enables reinvestment

Refreshed and expanded portfolio, solutions focus provides opportunities for growth in fast growing segments

• Genomics• Metabolomics• Proteomics

Page 20


Nicolas (Nick) Roelofs, Ph.D.Vice President and General ManagerLife Sciences Solutions

Page 23

APPENDIX

Page 24

Agilent Around the WorldGlobal footprint offers unmatched service and support

Global headcount: 19,400

• Manufacturing: 7,30045% Asia Pacific18% Europe37% Americas

• R&D: 3,30034% Asia Pacific 17% Europe49% Americas

• Sales & Marketing: 6,00040% Asia Pacific 20% Europe40% Americas

• Administration: 2,800 47% Asia Pacific 19% Europe34% Americas

Asia Pacific

36%

Americas38%

Europe26%

Agilent FY07 Revenueby Geography

Page 25

62 2

38

3

Life Sciences17%

Communications24%

General Purpose36% Chemical

Analysis23%

Agilent Revenue DistributionQ108 by market and sub-market

REVENUE BY MARKET ADDITIONAL SUB-MARKET DETAIL

Chemical Analysis

Life Sciences

General Purpose

Communications

ACADEMIC & GOVERNMENT

PHARMA, BIOTECH,CRO & CMO

19%5%

12%

OTHER GENERAL INDUSTRY

AEROSPACE & DEFENSE

COMPUTER & SEMICONDUCTORS

5%6%

2% 2%

3 D

ENVIRON-MENTAL

FORENSICS

FOOD

PETROCHEMICAL

13%

4%

WIRELESS MFG.

EDANETWORKI&M

WIRELESSR&D

BROADBANDR&D/MFG

NETWORKMONITORING

8%

MATERIALS SCIENCE

%% %

%

%

%

Page 26

EM Market Environment & Growth Drivers$18 billion market

GENERAL PURPOSE COMMUNICATIONSElectronic Measurement

GENERAL PURPOSE COMMUNICATIONSElectronic Measurement

Market Growth Range 5-6%Agilent Expected 2008 Growth Range 4-6%

Key Growth Drivers:• Network convergences• Mobile internet• R&D and design verification spending• Digital and Radio Frequency (RF) Convergence

Actions•Wireless R&D solutions - WiMax, LTE and emerging 3.9G technologies•Broad-based partnerships •Lower cost solutions for handset manufacturing

$9B $9B

Market Growth Range 5-6%Agilent Expected 2008 Growth Range 4-6%

Key Growth Drivers:• A/D test modernization • Homeland Security driving surveillance• Growing R&D & electronic manufacturing in Asia

Actions•Formulation of Signal Networks Division (SND)•Asia expansion•Expanded basic instrument portfolio

Page 27

FY 2008 Market Growth Assumptions

FY2007 Growth FY2008Segment Revenue % of Total Market Segment

EM $3,415 M 63% 5% 5%

BAM $2,005 M 37% 8% 14%Agilent $5,420 M 100% 6% 8%

Page 28

Agilent competitive comparisonsLast 12 Month results as of Q1 08 relative to our top competitors

YoY Rev Growth 7% 4% 11% 18% 8% 9%Inventory Days 120 115 83 80 106 101DSO 70 44 69 53 70 47ROIC 21% 24% 23% 29% 22% 26%

45% 42%50% 46% 47% 44%

12% 14%7% 8% 10% 12%

28% 29% 26% 27% 27% 29%

15% 16% 16%19%18%14%

0%

20%

40%

60%

80%

100%

EMG Blend

EMG BAMBlend

BAM Group Blend

Agilent

Op ProfitSG&AR&DCOGS

Page 22

RECONCILIATIONS

AGILENT TECHNOLOGIES, INC.RECONCILIATION OF OPERATING FREE CASH FLOW(IN MILLIONS)PRELIMINARY

2007 2004 Net cash provided by operating activities 969 307Less: Investments in property, plant and equipment 154 79Operating free cash flow 815$ 228$

The preliminary reconciliation of operating free cash flow is estimated based on our current information.

Operating free cash flow is a non-GAAP measure which management believes provides useful information to management and investors about the amount of cash generated by the business after the acquisition of property and equipment, which can then be used for strategic opportunities including investing in the Company's business and making strategic acquisitions. Our management uses this measure which is a common one in our industry to compare ourselves to our competitors and to measure our own performance. A limitation of operating free cash flow is that it does not represent the total increase or decrease in the cash balance for the period. Our management compensates for this limitation by monitoring and providing the reader with a complete GAAP statement of cash flows which includes net cash provided by operating activities.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

Years Ended October 31, 2007

AGILENT TECHNOLOGIES, INC.RECONCILIATION OF DAYS ON HAND (DOH)(IN MILLIONS)PRELIMINARY

Q4 '07 Q1 '08

GAAP

Costs of Products and Services 656 637 Net Inventory 643 674 GAAP Inventory Days 88 95

Non-GAAP

Costs of Products and Services 656 637 Ammortization of Intangibles, Others (9) (9) Restructuring and Asset Impairment (7) (8) Share-based comp & pension related (4) (7) Unallocated SPG/STS and business disposal costs - - Net Inventory (Charges)/Sales of previously written down inventory (6) (3) Adjusted Costs of Products and Services 630 610 Net Inventory 643 674 Non-GAAP Inventory Days 92 99

Non-GAAP DOH Formula:(Quarter-end net inventory * 90 Days)/(Current COGS - Inventory Charges - Non-GAAP Adjustments

GAAP DOH Formula:(Quarter-end net inventory * 90 Days)/(Current COGS)

The preliminary reconciliation of days on hand is estimated based on our current information.

AGILENT TECHNOLOGIES, INC.RECONCILIATION OF ROIC(IN MILLIONS)PRELIMINARY

AgilentNumerator: Q1'08 FY01 FY04 FY07Adjusted income from operations 194$ 150$ 465$ 858$ Less: Taxes and Other (income)/expense 41 54 138 194

Segment return 153 (a) 96$ 327$ 664$

Segment return annualized 612$

Denominator:Segment assets (b) 3,483$ 4,009$ 3,192$ 3,341$ Less: Net current liabilities (c) 642 938$ 778$ 755 Invested capital 2,841$ 3,071$ 2,414$ 2,586$

Average invested capital 2,714$ 3,082$ 2,700$ 2,485$

ROIC 23% 3% 12% 27%

ROIC calculation:(annualized current quarter segment return)/(average of the two most recent quarter-end balances of Segment Invested Capital)

(a) New Agilent return is equal to adjusted net income from continuing operations minus net interest income after tax. Please see "Adjusted Net Income and EPS Reconciliations" for a reconciliation of adjusted net income from continuing operations to GAAP income from continuing operations.

(b) Segment assets consist of inventory, accounts receivable, property plant and equipment, gross goodwill and other intangibles, deferred taxes and allocated corporate assets.

(c) Includes accounts payable, employee compensation and benefits, other accrued liabilities and allocated corporate liabilities.

Historical amounts were reclassified to conform with current period presentation.

The preliminary reconciliation of ROIC is estimated based on our current information.

Readers are reminded that non-GAAP numbers are merely a

Agilent

Return on invested capital (ROIC) is a non-GAAP measure that management believes provides useful supplemental information for management and the investor. ROIC is a tool by which we track how much value we are creating for our shareholders. Management uses ROIC as a performance measure for our businesses, and our senior managers' compensation is linked to ROIC improvements as well as other performance criteria. We believe that ROIC provides our management with a means to analyze and improve their business, measuring segment profitability in relation to net asset investments. We acknowledge that ROIC may not be calculated the same way by every company. We compensate for this limitation by monitoring and providing to the reader a full GAAP income statement and balance sheet.

AGILENT TECHNOLOGIES, INCRECONCILIATION FROM GAAP TO NON-GAAP NET INCOMETHREE MONTHS ENDED January 31, 2007(Unaudited)

Business Other,Restructuring Disposal and Share-Based Excess Donation to Principally

and Asset Infrastructure Compensation Software Agilent Other Adjustment for New Agilent(In millions, except per share amounts) GAAP Impairment Reduction Costs Expense Amortization Foundation Intangibles Taxes Non-GAAP

Orders Change Year Over Year 6% 1,250$ -$ -$ -$ -$ -$ -$ -$ 1,250$ 6% Change Year Over Year

Net revenue Change Year Over Year 10% 1,280$ -$ -$ -$ -$ -$ -$ -$ 1,280$ 10% Change Year Over Year

Costs and expenses: Cost of products and services Gross Margin 54.0% 589 (3) - (10) - - (6) - 570 55.5% Gross Margin Research and development As a % of Revenue 13.1% 168 (1) - (6) - - (2) - 159 12.4% As a % of Revenue Selling, general and administrative As a % of Revenue 33.4% 428 (5) (6) (20) (8) (20) (1) - 368 28.8% As a % of Revenue Total costs and expenses 1,185 (9) (6) (36) (8) (20) (9) - 1,097

Income from continuing operations Operating Margin 7.4% 95 9 6 36 8 20 9 - 183 14.3% Operating Margin

Other income (expense), net 28 - - - - - - - 28

Income from continuing operations before taxes 123 9 6 36 8 20 9 - 211

Tax ProvisionTax rate (incl. Valuation

Allowance) -22.0% (27) - - - - - - 76 49 23.2%Tax rate (incl. Valuation Allowance)

Net income (loss) 150$ 9$ 6$ 36$ 8$ 20$ 9$ (76)$ 162$

Net income per share - Basic and Diluted:

Basic 0.37$ 0.02$ 0.02$ 0.09$ 0.02$ 0.05$ 0.02$ (0.19)$ 0.40$ Diluted 0.36$ 0.02$ 0.01$ 0.09$ 0.02$ 0.05$ 0.02$ (0.18)$ 0.39$

Weighted average shares used in computing net income per share:

Basic 406 406 406 406 406 406 406 406 406 Diluted 418 418 418 418 418 418 418 418 418

The preliminary reconciliation from GAAP to Non-GAAP net income is estimated based on our current information.

Non-GAAP Adjustments

AGILENT TECHNOLOGIES, INCRECONCILIATION FROM GAAP TO NON-GAAP NET INCOMETHREE MONTHS ENDED January 31, 2008(Unaudited)

BusinessRestructuring Disposal and Share-Based Excess

and Asset Infrastructure Compensation Software Intangible Adjustment for(In millions, except per share amounts) GAAP Impairment Reduction Costs Expense Amortization Amortization Other Taxes Non-GAAP

Orders Change Year Over Year 12% 1,401$ -$ -$ -$ -$ -$ -$ -$ 1,401$ 12% Change Year Over Year

Net revenue Change Year Over Year 9% 1,393$ -$ -$ -$ -$ -$ -$ -$ 1,393$ 9% Change Year Over Year

Costs and expenses: Cost of products and services Gross Margin 54.3% 637 (8) (7) (9) - 613 56.0% Gross Margin Research and development As a % of Revenue 13.0% 181 (2) (5) - 174 12.5% As a % of Revenue Selling, general and administrative As a % of Revenue 31.7% 441 (2) (1) (18) (3) (4) (1) - 412 29.6% As a % of Revenue Total costs and expenses 1,259 (12) (1) (30) (3) (13) (1) - 1,199

Income from continuing operations Operating Margin 9.6% 134 12 1 30 3 13 1 - 194 13.9% Operating Margin

Other income (expense), net 13 - (2) - - - - - 11

Income from continuing operations before taxes 147 12 (1) 30 3 13 1 - 205


Allowance) 18% 27 - - - - - - 18 45 22%Tax rate (incl. Valuation Allowance)

Net income (loss) Net Margin 8.6% 120$ 12$ (1)$ 30$ 3$ 13$ 1$ (18)$ 160$ 11.5% Net Margin


Basic 0.32$ 0.03$ -$ 0.08$ 0.01$ 0.04$ -$ (0.05)$ 0.43$ Diluted 0.31$ 0.03$ -$ 0.08$ 0.01$ 0.03$ -$ (0.04)$ 0.42$ 8%


Basic 371 371 371 371 371 371 371 371 371 Diluted 382 382 382 382 382 382 382 382 382



AGILENT TECHNOLOGIES, INCRECONCILIATION FROM GAAP TO NON-GAAP NET INCOMETWELVE MONTHS ENDED OCTOBER 31, 2007(Unaudited)

Business RemeasurementRestructuring Disposal and Gain Share-Based Excess Donation to Loss for a One-Time

and Asset Infrastructure on Sale of Compensation Software Intangible Agilent Intercompany Adjustment for(In millions, except per share amounts) GAAP Impairment Reduction Costs Assets Expense Amortization Amortization Foundation Transaction Other Taxes Non-GAAP

Orders Change Year Over Year 7% 5,441$ -$ -$ -$ -$ -$ -$ -$ -$ -$ -$ 5,441$ 7% Change Year Over Year

Net revenue Change Year Over Year 9% 5,420$ -$ -$ -$ -$ -$ -$ -$ -$ -$ -$ 5,420$ 9% Change Year Over Year

Costs and expenses: Cost of products and services Gross Margin 54.8% 2,451 (15) - - (31) - (30) - - (2) - 2,373 56.2% Gross Margin Research and development As a % of Revenue 12.6% 685 (7) - - (21) - - - - (4) - 653 12.0% As a % of Revenue Selling, general and administrative As a % of Revenue 31.4% 1,700 (16) (14) 9 (87) (26) (10) (20) - - - 1,536 28.3% As a % of Revenue Total costs and expenses 4,836 (38) (14) 9 (139) (26) (40) (20) - (6) - 4,562

Income from continuing operations Operating Margin 10.8% 584 38 14 (9) 139 26 40 20 - 6 - 858 15.8% Operating Margin

Other income (expense), net 86 - - (6) - - - - 4 5 - 89

Income from continuing operations before taxes 670 38 14 (15) 139 26 40 20 4 11 - 947


Allowance) 4.8% 32 - - - - - - - - - 177 209 22%Tax rate (incl. Valuation Allowance)

Net income (loss) Net Margin 11.8% 638$ 38$ 14$ (15)$ 139$ 26$ 40$ 20$ 4$ 11$ (177)$ 738$ 13.6% Net Margin


Basic 1.62$ 0.10$ 0.03$ (0.04)$ 0.35$ 0.07$ 0.10$ 0.05$ 0.01$ 0.03$ (0.45)$ 1.87$ Diluted 1.57$ 0.09$ 0.03$ (0.04)$ 0.34$ 0.07$ 0.10$ 0.05$ 0.01$ 0.03$ (0.43)$ 1.82$


Basic 394 394 394 394 394 394 394 394 394 394 394 394 Diluted 406 406 406 406 406 406 406 406 406 406 406 406



Documents

Agilent - UBS Life Science RS - library.corporate-ir.netlibrary.corporate-ir.net/library/10/103/103274/items/284497/Agilent... · Weakness seen Semiconductor markets. ... GSK, Novartis,